
    
      A post marketing surveillance to determine the type and incidence of oro/nasopharyngeal or
      pulmonary adverse events that may occur in patients treated with commercially available
      TyvasoÂ®(treprostinil) Inhalation Solution. A comparison will be made to the type and
      incidence of events in patients receiving other FDA approved therapies for pulmonary arterial
      hypertension, as a control measure.
    
  